Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results

RH Guymer; CM Markey; IL McAllister; MC Gillies; AP Hunyor; JJ Arnold; A Chang; A Syed; G Broadhead; T Pham; T Hong; L Wong; M Zhu; S Burnett; N Joachim; W Wijeyakumar; G Manalang; C Mhlanga; N Joachim; K Spooner; P Mitchell; S Foran; C Wilson; V Cossatto; L Waniganayke; V Mai; R Atif; L Wa; S Maharaj; D Liong; C Matic; K Tran; S Jas; D Gibbs; S Wickremasinghe; L Lim; S Sandhu; T Nguyen; D Qatarneh; H Razavi; E Chong; M Little; G Bhardwau; M Ayres; M Chen; D Ong; K Creese; T Drew; C D'Sylva Parfett; T Pejnovic; T Chau; S Sanmugasundram; M Kolic; E Glatz; TM Tonder; A Luckie; S Heery; T Steele; B Matthews; J Croft; A Breen; B Gabriel; M Anderson; M Dodds; M Dwyer; B Brown; J Dwyer; I Fu; H Macauley; J Wong; R Chalasani; C Lim; S Huynh; T Nolan; J Leong; K Lau; S Kumar; T Nguyen; J Bitar; H Ahern; A Ali; N Zamora; A Lai; R Moussa; C Do; N Verma; G Bylsma; A Traill; B Curry; A Paprotny; A Ayesa; A Johns; Z Ujjainwala; A Maver; D Chan; J Chang; HK Kang; G Stringfellow; T Tan; H Cass

Journal article

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results

RH Guymer, CM Markey, IL McAllister, MC Gillies, AP Hunyor, JJ Arnold, A Chang, A Syed, G Broadhead, T Pham, T Hong, L Wong, M Zhu, S Burnett, N Joachim, W Wijeyakumar, G Manalang, C Mhlanga, N Joachim, K Spooner Show all

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2019

DOI: 10.1016/j.ophtha.2018.11.025

Abstract

Purpose: To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a treat-and-extend (T&E) regimen can achieve similar visual acuity (VA) outcomes as treatment aimed at resolving all SRF. Design: Multicenter, randomized, 24-month, phase 4, single-masked, noninferiority clinical trial. Participants: Participants with treatment-naïve active subfoveal choroidal neovascularization (CNV). Methods: Participants were randomized to receive ranibizumab 0.5 mg monthly until either complete resolution of SRF and intraretinal fluid (IRF; intensive arm: SRF intolerant) or resolution of all IRF on..

View full abstract

University of Melbourne Researchers

Robyn Guymer Author

Sanj Wickremasinghe Author

Lyndell Lim Author

Elaine Chong Author

Grants

Funding Acknowledgements

The FLUID study was funded by Novartis Pharmaceuticals Australia Pty. Ltd. The sponsor participated in the design of the study; conducting the study; data management; data analysis; and preparation, review, and approval of the manuscript.